<DOC>
	<DOCNO>NCT00326963</DOCNO>
	<brief_summary>This single arm study evaluate efficacy , safety tolerability new investigational protease inhibitor ( PI ) plus background antiretrovirals plus Fuzeon ( 90mg sc bid ) HIV-1 infected , triple-class treatment-experienced , Fuzeon-naive adult . The new investigational PI administer accord procedure early access program patient enrol . The anticipated time study treatment 3-12 month , target sample size approximately 120 individual .</brief_summary>
	<brief_title>BLQ Study : A Study Protease Inhibitor With Fuzeon ( Enfuvirtide ) Treatment-Experienced Patients With HIV-1 .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; seropositive HIV1 ; enrol early access program new investigational PI ; naive Fuzeon , investigational PI ; treatmentexperienced 3 ARV class drug ( NRTI , NNRTI PI ) . female pregnant breastfeeding ; evidence active , untreated opportunistic infection ; malignancy require chemotherapy radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>